Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Veidekke: Historic construction project in Oslo

Veidekke's subsidiary Seby AS has signed a contract with Ekebergveien 1 AS (Clemens Eiendom and the Oslo Hospital Foundation) to expand and rehabilitate the Oslo Hospital property in the Gamlebyen district of Oslo. The contract is a design and build contract valued at NOK 407 million excluding VAT.The project includes complete rehabilitation of the existing building stock of 4,000 m2 in addition to the construction of 5,300 m[2] of new builds. Oslo Hospital is built on the site of a Franciscan monastery from the 1200s, and has from the 1500s until 2018 served as an infirmary and psychiatric

Proposals of Glaston Corporation’s Shareholders’ Nomination Board to the Annual General Meeting 2024

Glaston Corporation                            Stock Exchange Release            19.1.2024 at 11.30Proposal for the composition of the Board of DirectorsThe Nomination Board of Glaston Corporation proposes to the Annual General Meeting, due to be held on 9 April 2024, that the number of members of the Board of Directors shall be seven (7) until the closing of the Annual General Meeting 2025, and that the current members of the Board of Directors Veli-Matti Reinikkala, Sebastian Bondestam, Antti Kaunonen, Sarlotta Narjus, Arja Talma, Tero Telaranta and Michael Willome shall be re-elected

Altor successfully raises record fund

Altor has closed Altor Fund VI at its hard cap of EUR 3 billion from world leading investors, which makes this Altor’s largest fund ever raised. Altor will continue their focused strategy of investing in mid‐market companies in the Nordic and DACH region, with an increased focus on green transition investments.Altor has over the last 20 years consistently been ranked among the leading Private Equity firms globally based on long-term performance. Realized investments have generated a gross IRR of 29% and a money multiple of 3.0x. This performance has enabled Altor to raise its largest fund

Qvantum Industries expands network: New distributors in Czech Republic, Spain and Portugal

Swedish heat pump manufacturer Qvantum is rapidly expanding its distribution network. After establishing companies in UK, Germany, Netherlands and Hungary, distribution agreements have now been signed with major partners in Czech Republic, Spain, and Portugal.“Our aim is to change the way the cities of Europe are heated. To achieve this, we are now expanding the network of distributors necessary to make it happen,” says Lars Bierlein, Head of New Markets. The newest additions to the international network are Czech Republic, Spain, and Portugal. For Spain and Portugal a distribution

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 17 - 19 JANUARY 2024 In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 186/23 and 187/23.   Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Stig Frederiksen, Head of Investor Relations, tel.: +45 32 71 08 55, e-mail: sfr@norden.com

InDex Pharmaceuticals announces expected cash balance per March 31, 2024

19 January, 2024 – InDex Pharmaceuticals Holding AB (publ) (“InDex Pharmaceuticals”) today announced that remaining commitments for the company have been quantified, and the expected cash balance per March 31, 2024, amounts to SEK 180-190 million.The amount includes all closing costs for the phase III program CONCLUDE, even though activities for closing the phase III program will continue also after March 31, 2024. The company will have additional operating costs required to fulfill obligations of a listed company after March 31, 2024 amounting to SEK 0.6-0.8 million per month. InDex

Risk Intelligence A/S announces outcome of long-term loan of approx. DKK 6.7 million

Risk Intelligence A/S (“Risk Intelligence” or "the Company") announces that the Company has secured a long-term loan of approx. DKK 6.7 million with board members and one shareholder.As published during the process of the Rights Issue including in the press release of 11 October 2023 the Company had a commitment of a long-term loan with EIFO, the Danish State Growth fund (former Vækstfonden) as part of the planned funding process. The Company has during December arranged a long-term loan from board members and one shareholder to reach the objective of fully removing short-term loan debt

Impala Bondco Plc - Non-payment of interest under the up to SEK 500m bonds issued by Impala Bondco Plc with ISIN NO0011117145 and agreed standstill with a majority of bondholders

Nottingham, 19 January 2024 - On 19 January 2024, Impala Bondco Plc (the "Company") was scheduled to make a payment of interest under the up to SEK 500,000,000 senior secured floating rate bonds with ISIN NO0011117145 (the "Bonds"). The Company has on the date hereof not made the payments of interest resulting in the occurrence of an event of default under the terms and conditions of the Bonds (the "Non-Payment"). For this reason, standstill undertakings have been entered into by the Company and holders of the Bonds representing more than 50 per cent. of the outstanding nominal amount,

Partnership with academia powers innovation at Wellspect HealthCare

Cross-sectoral partnerships are growing increasingly common in today’s business landscape as businesses seek to complement their own capabilities with the technologies and know-hows of different industries. In the life science industry, partnerships with academia are on the rise as a mean to push boundaries and accelerate innovation. Martin Lovmar (04th from the left on above photo), Principal R&D Scientist at Wellspect HealthCare and Adjunct Professor at Chalmers department of life science highlights that partnerships across industries serve different purposes. “In the quest to

Alleima receives a major order for steam generator tubes in the Nuclear segment

Alleima has received a major order for steam generator tubes in the Nuclear segment to a total value of approximately SEK 250 million.The order valued to approximately SEK 250 million, is from one of the world’s leading suppliers of nuclear power equipment and will be used in a nuclear plant in North America. It is classified as a major order (i.e. above SEK 200 million) and will be reported in the Tube division. The order was booked in the first quarter of 2024 and deliveries are scheduled for the first half of 2026. “We see a continued strong market within the Nuclear segment and we

Finnair adds flights to Nordic holiday destinations for the peak summer season: additional flights to Bodø and Trondheim in Norway, to Ivalo, Kittilä and Kuusamo in Finland and to Visby in Sweden

Finnair is adding flights to some of its most popular Nordic holiday destinations for the peak summer holiday season between end of June and August, in response to demand from both European and Asian travellers.   “Northern Europe with its fresh air and beautiful nature attracts travelers who see authentic experiences”, says Ole Orvér, Chief Commercial Officer, Finnair. “We offer holiday travelers excellent connections across the Nordics with smooth connections via our Helsinki hub.”  Finnair restores flights to Bodø, which is located right above the Arctic Circle in Northern Norway,

Enersense commits to Science Based Targets initiative to reduce greenhouse gas emissions

Enersense International PlcPress release 19 January 2024 at 10:00 a.m.Enersense has delivered a letter of commitment to the Science Based Targets initiative (SBTi), an international organisation that promotes ambitious climate action. In accordance with the Science Based Targets initiative, Enersense will set near-term emission reduction targets in line with SBTi’s criteria, which support the Paris Agreement's policy of limiting global warming to no more than 1.5 degrees Celsius. The science-based emission reduction targets will be set according to SBTi's schedule within two years of

Invitation to presentation of Midsona’s year-end report 2023 February 1, 2024

On February 1, 2024, at 8.00 CET, Midsona publishes its year-end report 2023. A presentation of the report will be held on the same day at 11.00 CET and can be followed via telephone conference or audio broadcast.Midsona invites investors, analysts and the media to a presentation of the year-end report, where CEO Peter Åsberg and CFO Max Bokander comment on the report. The presentation will be held at 11.00 CET and can be followed via telephone conference or audio broadcast. The report will be released at 8.00 CET and will be available at https://www.midsona.com/en/investors/reports/ The

Invitation to Rottneros’ year-end and interim report for Q4 2023

The interim report for the fourth quarter 2023 will be published on 1 February 2024, at 8.00 CET, and is followed by a live webcast at 12.00 CET the same day.All participants can follow the presentation via the web link: Rottneros' year-end report 2023 - Finwire  Questions can be asked via the link in advance or during the presentation.You can also watch the presentation afterwards via Rottneros'  Youtube channel and website: https://www.rottneros.com/investors/

Gradientech completes successful pre-clinical testing in the US

The diagnostics company Gradientech today announces the successful completion of its pre-clinical testing of the QuickMIC® system in the US.The pre-clinical testing of the QuickMIC system has included about a hundred clinical patient samples and was performed at two reputable US clinical laboratories. The evaluation of Gradientech’s ultra-rapid antibiotic susceptibility testing (AST) system showed excellent performance and holds promises for the upcoming FDA study. Results from the US pre-clinical study will be presented at significant microbiology conferences during the next year.   “

Nightingale Health joins Radical Health Festival Helsinki as Founding Partner to promote urgent global need for preventative health

Nightingale Health PlcPress release, 19 January 2024 at 10:00 a.m. (EET) Nightingale Health Plc (“Nightingale Health”), pioneer in health risk detection and preventative health, announced today that it is joining Radical Health Festival Helsinki as the Founding Partner. The festival will take place in Helsinki, Finland, on May 21–23, 2024. The theme for the event’s 2024 edition is ‘Deploying precision and prevention at scale’ and the festival is driven by a shared ambition to transform healthcare, deliver value, improve clinical and financial outcomes, and make health systems

Nel ASA: Receives purchase order for 10 MW of electrolyser equipment from Samsung C&T

(January 19, 2024 - Oslo, Norway) Nel Hydrogen Electrolyser AS, a subsidiary of Nel ASA (Nel, OSE:NEL), has signed a contract for 10 MW of alkaline electrolyser equipment for about EUR 5 million with Samsung C&T Corporation Engineering & Construction Group (‘Samsung C&T’) for its first off-grid green hydrogen production project to be deployed in South Korea. "We are thrilled to have been selected for this pilot project. Samsung C&T is dedicated to learning and developing within the green hydrogen industry, and we look forward to a productive and fruitful collaboration with the company,”

NYAB Oyj - Managers' Transactions

NYAB PlcMANAGERS' TRANSACTIONS19 January 2024 at 09:50NYAB Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: BINGAB Barents Investment Group ABPosition: Closely associated person(X) Legal person (1):Person Discharging Managerial Responsibilities In IssuerName: Johan LarssonPosition: Chief Executive OfficerIssuer: NYAB OyjLEI: 743700UX7WTIOT3QO547Notification type: INITIAL NOTIFICATIONReference number: 50266/4/6 ____________________________________________Transaction date: 2024-01-15

NYAB Oyj - Managers' Transactions

NYAB PlcMANAGERS' TRANSACTIONS19 January 2024 at 09:45NYAB Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Johan LarssonPosition: Chief Executive Officer Issuer: NYAB OyjLEI: 743700UX7WTIOT3QO547Notification type: INITIAL NOTIFICATIONReference number: 50263/4/6 ____________________________________________Transaction date: 2024-01-15Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)Instrument type: SHAREISIN: FI4000153515Nature of transaction: ACQUISITION  Transaction details(1):

NYAB Oyj - Managers' Transactions

NYAB PlcMANAGERS' TRANSACTIONS19 January 2024 at 09:50NYAB Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: BINGAB Barents Investment Group ABPosition: Closely associated person(X) Legal person (1):Person Discharging Managerial Responsibilities In IssuerName: Johan LarssonPosition: Chief Executive OfficerIssuer: NYAB OyjLEI: 743700UX7WTIOT3QO547Notification type: INITIAL NOTIFICATIONReference number: 50266/4/6 ____________________________________________Transaction date: 2024-01-15

Kimmo Rauhala appointed new CEO of LEDiL

Ratos has appointed Kimmo Rauhala as the new CEO of LEDiL. He joined LEDiL in 2020 as Chief Commercial Officer and is a proven leader with more than 30 years of international business experience. He will assume his new position today.Kimmo Rauhala’s long experience covers several different industries and business segments, including multi-disciplined engineering, design and automotive. Before he joined LEDiL in 2020 he came from a senior position in AQ Trafotek under the listed company AQ Group from the field of power electronics. He is experienced in leading global operations with large

Aiforia Technologies Plc updates its short and mid-term business targets

Aiforia Technologies Oyj, Inside information, January 19, 2024 at 09:30 a.m. EET. Aiforia's Board of Directors has approved the company's revised growth strategy and updated business targets.Aiforia wants to revolutionize pathology image analysis with the power of AI to provide better care for every patient. The company's vision is to be the global leader in AI-powered pathology image analysis.  Aiforia’s growth is supported by megatrends such as increasing rates of cancer and chronic diseases, aging populations, and personalized healthcare, which are increasing sample volumes at a time

Repurchase of Outokumpu’s own shares

Outokumpu OyjStock exchange releaseJanuary 19, 2024 at 9.30 am EETRepurchase of Outokumpu’s own shares On January 18, 2024, Outokumpu has completed repurchases of its own shares as follows (ISIN FI0009002422): +-------+----------------+------------------------------------+----------------+|Trading|Number of shares|Weighted average price / share, EUR*|Total cost, EUR*||venue | | | |+-------+----------------+------------------------------------+----------------+|CEUX |75,338 |4.0325

Investor Year-End Report 2023

“At the end of 2023, our adjusted net asset value reached an all-time-high, passing the SEK 800bn mark. During the year, adjusted net asset value growth and total shareholder return were 24 and 26 percent respectively, while the SIXRX return index gained 19 percent. This was the thirteenth straight year of Investor outperforming the stock market. In today’s complex environment, our focus remains on future-proofing our companies through strategic initiatives, while never compromising on efficiency.” Johan ForssellPresident & CEO of Investor Highlights during the fourth quarter ·

There are no items matching the current filter
There are no more items matching the current filter
Back to top